Article
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Dec 2023
Yu Helena A, Goto Yasushi, Hayashi Hidetoshi, Felip Enriqueta, Chih-Hsin Yang James, Reck Martin, Yoh Kiyotaka, Lee Se-Hoon, Paz-Ares Luis, Besse Benjamin, Bironzo Paolo, Kim Dong-Wan, Johnson Melissa L, Wu Yi-Long, John Thomas, Kao Steven, Kozuki Toshiyuki, Massarelli Erminia, Patel Jyoti, Smit Egbert, Reckamp Karen L, Dong Qian, Shrestha Pomy, Fan Pang-Dian, Patel Parul, Sporchia Andrea, Sternberg David W, Sellami Dalila, Jänne Pasi A
Abstract excerpt
PURPOSE: Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. We assessed the efficacy and safety of HER3-DXd in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.